Open AccessVenetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia
Author(s) -
Othman AlSawaf,
Carmen D. Herling,
Udo Holtick,
Christoph Scheid,
Paula Cramer,
Stephanie Sasse,
Bastian von Tresckow,
Armin Tuchscherer,
Kirsten Fischer,
Barbara Eichhorst,
Michael Hallek,
Lukas P. Frenzel
Publication year - 2019
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2018.212837
Subject(s) - obinutuzumab , chronic lymphocytic leukemia , venetoclax , rituximab , hematopoietic stem cell transplantation , transplantation , medicine , stem cell , cd20 , leukemia , immunology , cancer research , oncology , lymphoma , biology , genetics